Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAPHAEL study
2025-524819-37-00Phase 4Authorised
- Sponsor
- IRBLleida
- Start
- Mar 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised trial of semaglutide in obstructive sleep apnea hypopnea syndrome (OSAHS) (2 arms), sponsored by IRBLleida. Primary endpoint: Change in apnea–hypopnea index (AHI) at 6 months. Planned start Mar 2026; status: authorised.
02
Drugs
03
Conditions
obstructive sleep apnea hypopnea syndrome (OSAHS)
Beyond the preview
Go deeper on 2025-524819-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524819-37-00.